WebConcurrent use of amiodarone, fluconazole, rifampicin or phenytoin may increase the risk of major bleeding in some patients taking a direct oral anticoagulant (DOAC, also referred to as non-vitamin K [or novel] oral anticoagulant [NOAC]), a retrospective cohort study has found. 1 The study included data from 91,330 patients with nonvalvular atrial fibrillation (mean … WebFeb 7, 2024 · Both phenytoin and carbamazepine are combined P-glycoprotein and strong CYP3A4 inducers, theoretically reducing the anticoagulant effect of both warfarin and …
The Dangers of Drug Interactions With DOACs - Pharmacy Times
WebFeb 1, 2024 · Background: Carbamazepine and phenytoin are potent inducers of enzymes that metabolize oral anticoagulants. Objectives: To determine the clinical impact of drug-drug interactions between these... WebMar 6, 2024 · Drug-Drug Interactions Last Updated: March 6, 2024 Ritonavir, a strong cytochrome P450 (CYP) 3A4 inhibitor and a P-glycoprotein inhibitor, is coadministered with nirmatrelvir to increase the blood concentration of nirmatrelvir, thereby making it effective against SARS-CoV-2. changing flat kitchen cabinet doors
UpToDate
WebAug 30, 2024 · [13,92] Thus, the concomitant use of most DOACs with ritonavir- or cobicistat- boosted PIs (and with elvitegravir-cobicistat) should be avoided due to potential increases in the DOAC concentrations and potential risk of bleeding. [13,17] In general, the use of apixaban, betrixaban, edoxaban and rivaroxaban should be avoided in this setting. WebOct 1, 2024 · Direct oral anticoagulants are first-line agents for eligible patients for treating venous thromboembolism and preventing stroke in those with nonvalvular atrial fibrillation. Vitamin K antagonists... WebStrong inducers of P-gp, such as carbamazepine, phenytoin, rifampicin, and St John's Wort — plasma concentration of edoxaban may be reduced by these drugs. The manufacturer of edoxaban advises to avoid. If concurrent use is indicated, monitor for signs of thrombosis. changing flapper valve on toilet